Disclaimer: The Foundation does not offer medical advice (more details)
Uterine leiomyosarcoma (uLMS) is a rare, aggressive cancer with limited options. We focus on precision science-driven approaches, starting with defined molecular subtypes such as uLMS with PLAG1 overexpression, towards the goal of developing broader solutions against this cancer.
When uLMS is detected early, surgery offers a critical window of hope. But that window is shadowed by a harsh reality: a high risk of recurrence.
For too long, the only option has been “watchful waiting”, with regular monitoring, rising anxiety, and no proactive defense.
We believe that:
We are working toward a future where recurrence is not just monitored, but actively minimized; where we are ready to fight back if the disease returns.
We are: